Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10382 Plus Flumatinib in CML
NCT06530810Phase 1Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jul 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of TERN-701 in chronic myeloid leukemia (CML), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Maximum Tolerated Dose at Day 28. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
TERN-701
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT06530810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06530810.